A Phase IIa Multicenter Evaluation of The Safety And Efficacy of Weekly Administration of S-8184 Paclitaxel Injectable Emulsion In Second Line Treatment of Patients With Stage III or IV Colorectal Adenocarcinoma

NCT00034190 Phase 2 COMPLETED

Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or IV colorectal adenocarcinoma.

Details

Lead sponsor	Achieve Life Sciences
Phase	Phase 2
Status	COMPLETED
Enrolment	28
Start date	2002-03
Completion	2007-09

Conditions

• Colorectal Adenocarcinoma

Interventions

• S-8184 Paclitaxel Injectable Emulsion

Primary outcomes

• Determine the Objective Response Rate — When all patients have completed treatment

Countries

Russia